Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Plus Therapeutics Inc (PSTV)

Plus Therapeutics Inc (PSTV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,368
  • Shares Outstanding, K 5,896
  • Annual Sales, $ 4,910 K
  • Annual Income, $ -13,320 K
  • EBIT $ -15 M
  • EBITDA $ -14 M
  • 60-Month Beta 0.70
  • Price/Sales 1.28
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.50
  • Number of Estimates 2
  • High Estimate -0.43
  • Low Estimate -0.58
  • Prior Year -0.70
  • Growth Rate Est. (year over year) +28.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9250 +13.51%
on 12/19/24
1.4500 -27.59%
on 12/06/24
-0.2300 (-17.97%)
since 11/26/24
3-Month
0.9250 +13.51%
on 12/19/24
1.9400 -45.88%
on 09/27/24
-0.4900 (-31.82%)
since 09/26/24
52-Week
0.9250 +13.51%
on 12/19/24
2.6702 -60.68%
on 06/05/24
-0.8500 (-44.74%)
since 12/26/23

Most Recent Stories

More News
Plus Therapeutics Reports Promising Phase 1 Trial Results for Rhenium (186Re) Obisbemeda in Leptomeningeal Disease with Plans for Expanded Trials in 2025

Plus Therapeutics reports positive Phase 1 trial results for Rhenium (186Re) Obisbemeda in breast cancer-related leptomeningeal disease.Quiver AI SummaryPlus Therapeutics, Inc. has shared promising results...

PSTV : 1.0400 (-3.70%)
Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Breast Cancer Patients with Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium

PSTV : 1.0400 (-3.70%)
Plus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium

PSTV : 1.0400 (-3.70%)
Plus Therapeutics, Inc. Renews Master Services Agreement with Telix IsoTherapeutics to Secure Supply of Radiotherapeutic Isotope Re-186

Plus Therapeutics renews agreement with Telix IsoTherapeutics for cGMP Re-186 supply, supporting clinical trial demands for cancer therapy.Quiver AI SummaryPlus Therapeutics, Inc. has renewed its Master...

PSTV : 1.0400 (-3.70%)
Plus Therapeutics Expands Strategic Agreement with Telix IsoTherapeutics Group for Rhenium-186 Radioisotope Supply

PSTV : 1.0400 (-3.70%)
Plus Therapeutics Reports Promising Phase 1 Trial Results of Rhenium (186Re) Obisbemeda for Leptomeningeal Metastases, Secures FDA Approval for Expanded Studies

Rhenium (186Re) Obisbemeda shows promising results for leptomeningeal metastases, with favorable survival rates and FDA trial approval.Quiver AI SummaryPlus Therapeutics, Inc. announced the positive results...

PSTV : 1.0400 (-3.70%)
Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 SNO Annual Conference

PSTV : 1.0400 (-3.70%)
Plus Therapeutics to Present Positive FORESEE Clinical Trial Summary Demonstrating Utility of CNSideâ„¢ Cerebrospinal Fluid Assay in Diagnosis and Clinical Management of Patients with Leptomeningeal Metastases

PSTV : 1.0400 (-3.70%)
CNSide Diagnostics Presents Key Findings on Cerebrospinal Fluid Assay for Leptomeningeal Metastases at 2024 SNO Annual Meeting

CNSide Diagnostics presents findings on mutational changes in CSF for leptomeningeal metastases, aiding treatment selection.Quiver AI SummaryCNSide Diagnostics, a subsidiary of Plus Therapeutics, presented...

PSTV : 1.0400 (-3.70%)
Plus Therapeutics to Present Multi-Institutional Experience Using the CNSideâ„¢ Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases

PSTV : 1.0400 (-3.70%)

Business Summary

Plus Therapeutics Inc. is a clinical-stage pharmaceutical company. It engages in developing treatments for cancer and other diseases primarily in the United States. The company's product candidate consists of DocePLUS which are in clinical stage. Plus Therapeutics Inc., formerly known as Cytori Therapeutics...

See More

Key Turning Points

3rd Resistance Point 1.1433
2nd Resistance Point 1.1267
1st Resistance Point 1.1033
Last Price 1.0400
1st Support Level 1.0633
2nd Support Level 1.0467
3rd Support Level 1.0233

See More

52-Week High 2.6702
Fibonacci 61.8% 2.0035
Fibonacci 50% 1.7976
Fibonacci 38.2% 1.5917
Last Price 1.0400
52-Week Low 0.9250

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar